Mr Simon Brewster
Senior Research Fellow, Co-ordinating Tutor of Clinical Medicine
Consultant Urological Surgeon
Mr Simon Brewster graduated from Charing Cross Hospital Medical School in 1986, then undertook his surgical training, FRCS exams and research for his MD in Bristol. In 1998, he was appointed as Consultant Urological Surgeon in Oxford with a clinical and research interest in prostate cancer and prostatic disease. He has been involved with teaching, interviewing and supporting students at Hertford since 2002. During years 4-6, the Hertford medical students receive regular exam-focused bedside clinical teaching at the John Radcliffe & Churchill hospitals from Mr Brewster and Dr Henry Bettinson, College Lecturer & Consultant Respiratory Physician.
No specific undergraduate teaching, though Simon takes occasional prospective medical students for work experience.
University of Oxford Clinical (Years 4-6) Medical Students:
- Lecturing: annual Core Surgical and Final MB Revision courses on prostate disease since 1998;
- Teaching departmental Lead: weekly 1-hour tutorials; Organiser, teaching timetable since 1998;
- Examining: BM Finals and Years 4 & 6 internal exams since 1998;
- Fellow & Clinical Tutor, Hertford College, Oxford, 2002-; provision of bedside teaching, pastoral support & educational supervision to all Year 4-6 students of the College.
- Voted Consultant Teacher of the Year (2nd place) 2011 and 2015 by Year 6 students.
- Clinical Supervisor, training ST2 & SpR staff since1998;
- ISCP Educational Supervisor to 2 SpRs since 2009.
1. Secretary & UK Representative, European Association of Urology Section of Oncological Urology (ESOU): Minuting meetings, planning educational workshops;
2. Chairman, annual ESOU Scientific Meeting, London, Jan 21-23 2011. This involved venue selection, arranging the scientific programme & inviting 50 Faculty members.
3. 28 invited lectures since 1995 to UK and international learned societies & scientific meetings on prostate cancer topics;
4. Member , British Assoc. Urological Surgeons (BAUS) Section of Oncology and Education Committees 2011-5;
5. Lecturer, BAUS FRCS Urol. Revision Course 2005-8, 2012.
Basic Science Research: Since 1998, co-supervised research leading to 4 higher degrees. Collaboration with Dr Val Macaulay: In 2009 Mr B Turney, studying the targeting of the insulin-like growth factor type 1 receptor (IGF1R) for the potential treatment of prostate cancer (PC), was awarded his PhD. In 1999 Mr G Hellawell started this work, replaced in 2002 by Mr M Rochester. Both have now been awarded MDs. Work is continuing, with a grant application to study dietary intervention and IGF1R alterations in PC patients. Collaboration with Prof W Bodmer: another research Fellow studied the role of wnt signal transduction pathway in PC and received an MD January 2007.
Current Clinical Research:
1. Senior investigator of group examining the impact of introducing multi-parametric MRI into the protocol of active surveillance for men with low-risk localised prostate cancer in Oxfordshire.
2. Investigator, UK multi-centre PART (phase II PC HIFU focal therapy versus radical prostatectomy) randomised trial;
3. Investigator, VANCE neoadjuvant vaccine followed by radical prostatectomy or active surveillance phase I trial;
4. As multi-disciplinary team PC Lead, I recruit patients to the UK Familial prostate cancer study, national STAMPEDE & RADICALS randomised trials.
ADVANCES IN UROLOGY 2015-2016. Brewster S, Biers S, Challacombe B, Cresswell J, Sinclair A & Smith D. J Clin Urol 2017; 10: 39-48.
UROLOGICAL RECOMMENDATIONS FROM THE NICE GUIDELINE, JUNE 2015: SUSPECTED CANCER: RECOGNITION AND REFERRAL
Jefferies ER & Brewster SF on behalf of the BAUS Section of Oncology. BJUI 2016; 117: 857-860. doi: 10.1111/bju.13355.
PROSTATE BIOPSY – WHAT IS THE MOST APPROPRIATE APPROACH?
Richard Bryant & Simon Brewster. BJUI Knowledge 2016 https://app.tessello.co.uk/CourseStore/clients/BJUI/71712
ADVANCES IN UROLOGY 2014–2015.
Jo Cresswell, Marc Laniado, Andrew Sinclair, Daron Smith, Suzie Venn, Simon Williams & Simon Brewster. Journal of Clinical Urology 2016, 9: 223–229.
CONTEMPORARY PRACTICE AND TECHNIQUE RELATED OUTCOMES FOR RADICAL PROSTATECTOMY IN THE UNITED KINGDOM: A REPORT OF NATIONAL OUTCOMES
Laird A, Fowler S, Good S, Stewart G, Srinivasan, Cahill, Brewster SF, McNeill A. on behalf of BAUS Section of Oncology. BJUI 2015: 115: 753-763.
NICE GUIDELINES ON PROSTATE CANCER ACTIVE SURVEILLANCE: IS UK PRACTICE LEADING THE WORLD?
Streeter E & Brewster SF. BJUI 2015: 115; 12-13.
IMPROVING THE DIAGNOSIS AND TREATMENT OF HIGH-RISK LOCALISED OR LOCALLY ADVANCED PROSTATE CANCER IN THE UK
Payne H, Khoo V, Clarke N, Beresford M, Moore C, Aslett P, Bahl A, Bhatt R, Greg Boustead G, Brewster S & Kirby R. Health Trends 2015: 6; 26-30.
IMPROVING THE SURGICAL TREATMENT OF HIGH-RISK LOCALISED OR LOCALLY ADVANCED PROSTATE CANCER IN THE UK
Kirby R, Payne H, Khoo V, Clarke N, Beresford M, Moore C, Aslett P, Bahl A, Bhatt R, Greg Boustead G & Brewster S. Health Trends 2015: 6; 29-32.
VARIATION BETWEEN SPECIALIST UROPATHOLGISTS IN REPORTING EXTRAPROSTATIC EXTENSION AFTER RADICAL PROSTATECTOMY.
Bryant RJ, Schmitt AJ, Roberts ID, Gill S P,Browning L , Brewster SF, Hamdy FC, Verrill CJ. J Clin Pathol 2015; 68: 465–472.
ESTABLISHING NURSE-LED ACTIVE SURVEILLANCE FOR MEN WITH LOCALISED PROSTATE CANCER: DEVELOPMENT AND FORMATIVE EVALUATION OF A MODEL OF CARE IN THE PROTECT TRIAL.
Julia Wade, Peter N Holding, Susan Bonnington, Leila Rooshenas, J Athene Lane, C Elizabeth Salter, Kate Tilling, Mark J Speakman, Simon F Brewster, Simon Evans, David E Neal, Freddie C Hamdy, Jenny L Donovan For The Protect Study Group. BMJ Open 2015;5:e008953.doi:10.1136/bmjopen-2015-008953 22 Sept 2015
UROLOGICAL RECOMMENDATIONS FROM THE NICE GUIDELINE, JUNE 2015: SUSPECTED CANCER: RECOGNITION AND REFERRAL
Jefferies ER & Brewster SF on behalf of the BAUS Section of Oncology. BJUI 2015 epub ahead of publication; doi: 10.1111/bju13355.
ALTERED EXPRESSION OF MARKERS OF EPITHELIAL-TO-MESENCHYMAL TRANSITION AT THE EXTRAPROSTATIC EXTENSION COMPONENT OF LOCALLY INVASIVE PROSTATE CANCERS
Bryant RJ, Schmitt AJ, Roberts ID, Gill S P,Browning L , Brewster SF, Hamdy FC, Verrill C. J.. Submitted to Oncotarget 2015.
GLOVE AT FIRST SIGHT – HISTORY OF THE FIRST SURGICAL RUBBER GLOVE, Bhatt JR, Wood IRG, Hobbs CP & Brewster S. Eur Urol 2013; 12(1) Supp 1077
PSA KINETICS IN THE DIAGNOSIS AND MANAGEMENT OF PROSTATE CANCER
Vickers A & Brewster SF. British Journal of Medical and Surgical Urology 2012: 5; 162-168.
Serial analysis of resected prostate cancer suggests up-Regulation of type 1 IGF receptor with disease progression.
Turney B W, Turner GDH, Brewster SF & Macaulay V. British Journal of Urology International 2011: 107; 1488-1499.
Testicular Torsion: A painful turn of events.
Kirthi, V & Brewster S. Student BMJ 2011: 19; 26-27.
Focal therapy is an option for the majority of localised prostate cancers: A histopathological study of contemporary UK radical prostatectomies
Aslam MA, Turner, G, Brewster SF. British Journal of Medical and Surgical Urology 2011: 4; 166-170.
Prostate cancer: to screen or not to screen.
Bailey SJV & Brewster SF. Arch. Esp. Urol. 2011: 64 (5); 406-418.
EXAMINATION OF THE MALE GENITALIA
Kirthi V., Ellis B. & Brewster S. Journal of Clinical Examination 2011: 11; 22-31.
The Digital rectal examination
Shirley A & Brewster SF. Journal of Clinical Examination 2011: 11; 1-12.
High-intensity focused ultrasound for localised prostate cancer: initial experience with a 2-year follow-up.
Leslie T & Brewster S. British Journal of Urology International 2010: 105, 726-727.
Challenging the EAU 2009 Guidelines on Testis Cancer: The Risk-Adapted Management of Stage I Nonseminomatous Germ Cell Tumours: Surveillance Yields Equal Results With Less Toxicity.
Brewster SF. European Urology Supps. 2010: 9; 459-461.
FOCAL THERAPY FOR PROSTATE CANCER; POSSIBILITIES AND LIMITATIONS.
Eggener S, Salomon G, Scardino, PT, De la Rosette J, Polascik TJ, Brewster S. Eur Urol 2010: 58; 57-64.
Does the presence of robotic surgery affect demographics in patients choosing to undergo radical prostatectomy? A multi-center contemporary analysis.
Philippa J. Cheetham, Daniel J. Lee, Anna Rose-Morris, Simon F. Brewster, Ketan Badani. J Robotic Surgery 2010.
PROSPECTIVE STUDY OF CURRENT PROSTATE BIOPSY PRACTICES AMONG ONCOLOGICAL UROLOGISTS
Brewster S, Turkeri L, Brausi M, Ravery V, Djavan B. Canadian J Urol 2010: 17; 5071-5076.
MUTATIONS IN THE AXIN1 GENE IN ADVANCED PROSTATE CANCER
Yardy GW, Bicknel DC, Wilding JL, Bartlett S, Lui Y, Winney B, Turner G, Brewster SF & Bodmer WF. Eur Urol 2009: 56; 486-494.
Single focus prostate cancer on TRUS biopsy – Does size matter? Tsang WC, Kaur J, Robert I and Brewster S. Eur Urol 2008: 7, 274.
NICE GUIDANCE ON PROSTATE CANCER AND THE ROLE OF ACTIVE SURVEILLANCE FOR LOW-RISK, LOCALISED DISEASE. Marsh HP & Brewster SF. BMJ Rapid Response March 2008.
LOW-RISK LOCALISED PROSTATE CANCER: ARE WE READY TO RECOMMEND ACTIVE SURVEILLANCE AS THE PREFERRED OPTION? Brewster SF. British Journal of Urology International 2008: 102, 923-926.
Are 2 repeat prostate biopsies sufficient to determine the outcome of High-Grade PIN and ASAP on initial prostate biopsy? W.C. Tsang, I.S.D Roberts and S. Brewster. Eur Urol 2007: 6, 123.
High-intensity focussed ultrasound for localised prostate cancer: intra-operative determinants of biopsy-proven failure using the Sonablate 500 system. Calleary J, Leslie T, Illing R, Kennedy J, Brewster S, Allen C, Freeman A & Emberton M. Eur Urol 2007: 6, 123.
Patients’ perceptions of transrectal prostate biopsy: a qualitative study. Chapple AB, Ziebland S, Brewster S & Mcpherson A. Eur J Cancer 2007: 16, 215-221.
A RANDOMISED CONTROLLED TRIAL OF TOPICAL GTN BEFORE TRUS-GUIDED BIOPSY (letter). Brewster S & Rochester M. BJU International 2007: 100, 1412-1413.
The Wnt signaling pathway is a potential therapeutic target in prostate cancer. Yardy GW & Brewster SF. BJU International 2006; 98, 719-21.
A double-blind, randomized, controlled trial of topical glyceryl trinitrate foR transrectal ultrasound guided prostate biopsy. RochesterMA, Le Monnier K, Brewster SF. J Urol. 2005: 173(2):418-20.
Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. RochesterMA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. Cancer Gene Ther. 2005: 12(1): 90-100.
LONG-TERM OUTCOMES AND MORBIDITY AFTER I125 BRACHYTHERAPY FOR LOCALISED PROSTATE CANCER: AN EARLY UK SERIES. Hellawell GO, Le Monnier K,Davies D, Fellows GJ, Whipp E and Brewster SF. Clinical Oncology 2005: 17, 68.
Wnt SIGNALLING and PROSTATE CANCER. Yardy GW & Brewster SF. Prostate Cancer & Prostatic Diseases 2005: 8, 119-126.
THE TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR IS OVER-EXPRESSED IN BLADDER CANCER, AND TARGETING BY RNA INTERFERENCE REDUCES IN VITRO SURVIVAL. RochesterMA, Patel N, Hellawell GO, Brewster SF & Macaulay VM. J Urol 2004: 171, S195.
GENETICS FOR UROLOGISTS. RochesterMA, & Brewster SF. BJUI EBU Update 2004: 94, 232.
OPPORTUNITIES AND OUTCOMES IN EARLY PROSTATE CANCER: A COMMENTARY ON POLICY, PATIENT PERSPECTIVES, TRIALS AND STRATEGIES
M.R. Feneley & S. Brewster
British Journal of Urology International 2003; 91, 177-178.
CHEMOSENSITISATION OF HUMAN PROSTATE CANCER USING ANTISENSE AGENTS TARGETING THE TYPE-1 INSULIN-LIKE GROWTH FACTOR RECEPTOR
GO Hellawell, D.J.P. Ferguson, SF Brewster & VM Macaulay
BJU International 2003; 91, 271-277.
THE USE OF ASPIRIN WITH PC-SPES MAY NOT PREVENT PULMONARY EMBOLISM
SM Biers & SF Brewster
British Journal of Urology International 2003; 91, 428.
Editorial Comment on BIOCHEMICAL DISEASE-FREE SURVIVAL IN PATIENTS WITH A HIGH PSA AND
CLINICALLY-LOCALIZED PROSTATE CANCER AFTER RADICAL PROSTATECTOMY by Brandli DW et al.
British Journal of Urology International 2003; 92, 19-22.
SF Brewster. British Journal of Urology International 2003; 92, 22-23.
p53 and bcl-2 IMMUNOHISTOCHEMISTRY IN PREOPERATIVE BIOPSIES AS PREDICTORS OF
BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY
JD Oxley, MH Winkler, K Parry, SF Brewster, C Abbott & DA Gillatt. BJU International, 2002; 89, 27-32.
GROWTH FACTORS AND THEIR RECEPTORS IN PROSTATE CANCER
GO Hellawell &SF Brewster. BJU International, 2002; 89, 230-240.
SF Brewster. J Ass Ch Phys Wom Health 2002; 90, 17-18.
CAN SAW PALMETTO HELP IN PROSTATE CANCER?
SF Brewster. Pulse 2002; 62, 60.
Screening for prostate cancer in the UK
J Ord & SF Brewster.
BMJ Rapid Response 18/04/2002
EXPRESSION OF THE TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR IS UP-REGULATED IN PRIMARY PROSTATE CANCER AND COMMONLY PERSISTS IN METASTATIC DISEASE
GO Hellawell, GH Turner, DR Davies, R Poulsom , SF Brewster & VM Macaulay
Cancer Research 2002; 62, 2942-2950.
BMJ USA : Letter
S Brewster, M Feneley & R Kirby. BMJ Rapid Response 4/10/2002
THE ATTITUDES AND USES OF ALTERNATIVE THERAPIES BY UK PROSTATE CANCER PATIENTS – isn’t it
time we were in the know?.
P Cheetham, K LeMonnier & SF Brewster. Prostate Cancer and Prostatic Diseases, 2001; 4, 235-241.
UROLOGY AND THE INTERNET: AN EVALUATION OF INTERNET USE BY UROLOGY PATIENTS AND OF INFORMATION AVAILABLE ON UROLOGICAL TOPICS.
G.O. Hellawell, KJ Turner, KJ Le Monnier and SF Brewster. British Journal of Urology, 2000; 86: 191-194.
UP-REGULATION AND ALTERED DISTRIBUTION OF IGF-1 RECEPTOR IN HUMAN PROSTATE CANCER.
G.O. Hellawell, D.R. Davies, H. Turley, SF Brewster and V.M. Macaulay. British Journal of Urology, 2000; 86: 360-393.
DIGITAL RECTAL EXAMINATION BY MEDICAL STUDENTS AND HOUSE OFFICERS. TAUGHT, NOT DONE.
K.J. Turner and S.F. Brewster. Prostate Cancer and Prostatic Diseases, 2000; 3, 128-129.
P53, BCL-2, CD44 AND E-CADHERINAS PREOPERATIVE PREDICTORS OF TREATMENT FAILURE AFTER
Simon F Brewster, Jon Oxley, Clive Abbott and David A Gillatt. Jounal of Urology, 1999; 161: 1238-1243.
INACTIVATION OF THE RETINOBLASTOMA SUSCEPTIBILITY GENE (RB1) IN EYE AND BLADDER
TUMOURS FROM THE SAME PATIENT
Simon F Brewster, Margaret Knowles, David Poller and J Gingell. British Journal of Urology, 1998; 81: 494-495.
Antimicrobial prophylaxis for prostatic biopsy
SF Brewster. Current Opinion in Urology 1997; 7: 57-60.
Reply to letter commenting on “Antimicrobial prophylaxis for transrectal biopsy of the
prostate: a prospective randomised trial”.
SF Brewster, AG MacGowan & JC Gingell. British Journal of Urology 1995; 76: 351-354. British Journal
of Urology 1996; 77: 618-619.
The tumour suppressor gene nm23-H1 in bladder cancer
SF Brewster & JC Gingell. British Journal of Urology 1996; 78: 321-322(letter).
PROBLEMS IN DIAGNOSIS AND MANAGEMENT OF GOITRE IN CHILDHOOD AND ADOLESCENCE.
AJ Webb, SF Brewster & D Newington. British Jourmal of Surgery 1996; 83: 1586-1590.
THE PROSPECTS OF GENE THERAPY FOR UROLOGICAL MALIGNANCY
SF Brewster. Current Medical Literature: Urology 1995; 1: 31 - 36.
Antimicrobial prophylaxis for transrectal biopsy of the prostate: a prospective
SF Brewster, AG MacGowan & JC Gingell. British Journal of Urology 1995; 76: 351-354.
GENE THERAPY FOR CANCER: WHAT’S IT ALL ABOUT?
SF Brewster. Hospital Update 1994 ; 20 : 140 - 150.
SOMATIC ALLELIC LOSSES AT TUMOUR SUPPRESSOR GENES DCC, p53, nm23-HI AND APC LOCI IN
HUMAN PROSTATIC CARCINOMA
SF Brewster, S Browne, KW Brown. Journal of Urology 1994 ; 151: 1073 - 1077.
PELVIC APPENDICITIS IN YOUNG MALES MASQUERADING AS CYSTITIS
SF Brewster, A Lovering, J McLoughlin
Journal of the RoyalCollege of Surgeons of Edinburgh 1994; 39: 119 - 120.
GENE THERAPY IN UROLOGICAL ONCOLOGY : PRINCIPLES, STRATEGIES AND POTENTIAL
SF Brewster and JW Simons
European Urology, 1994; 25: 177 - 182.
THE ACUTE SURGICAL ADMISSION: IS MORTALITY PREDICTABLE IN THE ELDERLY?
RH Kennedy, AM Al-Mufti, SF Brewster, EN Sherry, TR Magee, TT Irvin. Annals of the RoyalCollege of Surgeons 1994; 76: 342 - 345.
SCREENING FOR PROSTATE CANCER IN GENERAL PRACTICE -RESULTS OF A 3-YEAR FOLLOW-UP
SF Brewster, T Kemple, A MacIver, P Astley and JC Gingell
British Journal of Urology 1994; 74: 556 - 558.
LOSS OF HETEROZYGOSITY ON CHROMOSOME 18q IS ASSOCIATED WITH MUSCLE-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER
SF Brewster, JC Gingell and KW Brown
British Journal of Cancer 1994; 70: 697-700.
THE ROLE OF CANCER GENES IN THE DEVELOPMENT OFPROSTATE CANCER
Endocrine-related Cancer 1994; 3: 27 - 39.
ADVANCED PROSTATE CANCER - WHAT’S NEW IN HORMONALMANIPULATION?
SF Brewster and DA Gillatt
British Journal of Hospital Medicine 1993; 49 : 710-715.
A FATAL ANAEROBIC SEPSIS FOLLOWING TRANSRECTAL BIOPSY OF A RARE PROSTATIC TUMOUR
SF Brewster, N Rooney, J Kabala, RCL Feneley
British Journal of Urology 1993; 77 : 977 - 978.
INTRA-VESICAL FOREIGN BODIES - A FIVE-YEAR REVIEW
SD Eckford, RA Persad, SF Brewster, JC Gingell
British Journal of Urology 1992; 69: 41 - 45.
TUMOUR SUPPRESSOR GENES IN URINARY TRACT ONCOLOGY -A REVIEW
SF Brewster, JC Gingell, KW Brown
British Journal of Urology 1992; 70: 585 - 590.
TRANSRECTAL BIOPSY - RESULTS OF ANTIMICROBIAL PROPHYLAXIS QUESTIONNAIRE
British Journal of Urology 1992; 70: 596.
A MALE PSEUDOHERMAPHRODITE WITH NOONAN’S SYNDROME
SF Brewster, RM Kennedy, PJB Smith
British Journal of Urology 1992; 67: 96 - 97.
THE VARICOSE VEIN WAITING LIST - RESULTS OF A VALIDATION EXERCISE
SF Brewster, S Nicholson, JR Farndon. Annals of the RoyalCollege of Surgeons 1991; 73: 223 - 226.
CAN KNEE REPLACEMENTS BE ASSESSED BY POST?
SF Brewster, JH Newman. Health Trends 1991; 23: 113 - 114.
THE DEVELOPMENT OF THE LIGAMENT OF THE HEAD OF THE FEMUR
SF Brewster. Clinical Anatomy 1990; 4: 245 - 255.
THE DEVELOPMENT AND DIFFERENTIATION OF HUMAN SEMINAL VESICLES
SF Brewster. Journal of Anatomy 1985; 143: 45 - 55.
UROLOGY: A HANDBOOK FOR MEDICAL STUDENTS
SF Brewster, J Reynard, J Noble and D Cranston. Simon edited this book of 12 chapters, five of which were written by him. Published April 2001. Publisher Bios Scientific, Oxford, UK.
This book has been reviewed by Elwell, V.A. and Vale, J.. BJU International 2002; 89, 796. “This book provides a solid foundation and introduction to Urology in a manner that is clear, concise and informative”…”a pleasure to read”.
OXFORD HANDBOOK OF UROLOGY
J Reynard, SF Brewster, S Biers. Oxford University Press, 3rd edition 2013. 1st edition published 2005; 2nd edition 2009. This book has been well-received by trainee urological surgeons. It has been translated into four languages and is available in digital format. Total sales have exceeded 20000. A 4th edition is in press, due to publish February 2018.
The 2nd edition was reviewed by McGuire B.B. BJU International 2010: 105, 1187. “The Oxford Handbook of Urology is an absolute “must-have” on every trainee’s shelf” … “I cannot recommend this textbook more to readers; if you are only going to read one textbook in your life, this should be it!”
In all editions 15,000 copies have been sold.
TUMOUR SUPPRESSOR GENES IN PROSTATE CANCER
SF Brewster. Chapter in “Molecular Biology of Prostate Cancer” Eds. M Wirth, Schmiz-Dra
ger. Publisher W De Gruyter, Berlin 1998.
The history of androgen deprivation in prostate cancer.
M. Pitman, P Cheetham & SF Brewster. Chapter in “The future of androgen deprivation for prostate cancer” Ed. Bob Djavan. Publisher Orion Pharma, 2011.